Search results
Metastatic multiple myeloma: Symptoms, treatment, and more
Medical News Today· 3 days agoMetastatic multiple myeloma is a form of cancer of the bone marrow that has spread to other parts of...
MRD endpoint expected to usher new era for MM therapies
Clinical Trials Arena via Yahoo Finance· 5 days agoDr. Banerjee believes that MRD as an endpoint could potentially be adopted for use in other cancers....
Exposed to Agent Orange at US bases, vets face cancer without VA help
Military Times via Yahoo News· 12 hours agoAkey, who also worked with Elder, runs a Facebook group and keeps a list of people stationed on the...
HaemaLogiX welcomes former Australian Federal Minister for Health Professor the Hon Greg Hunt to the...
WPRI Providence· 7 days agoHaemaLogiX Ltd, a clinical stage biotech developing novel immunotherapies for patients with blood cancers and B-cell diseases, is pleased to announce the appointment of Professor the Hon Greg ...
BioLineRx Announces Abstract on Pilot Study Data from Phase 2 Combination Clinical Trial Evaluating...
FOX 23 News Albany· 3 days agoBioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing...
Congress evaluates how to lower prescription prices by increasing competition
WHIO-TV 7 Dayton· 5 days agoRoughly 30% of Americans say they’re struggling to pay for prescription drugs. “My doctors have me...
It's not just for dead people: Battle over how safe formaldehyde is to the living brews
The Center Square· 4 days agoIn the nearly 20 years since then, there has been an ongoing debate on how dangerous formaldehyde...
HI-Bio Announces Positive Results from Phase 2 Study of Felzartamab for Late Antibody-Mediated...
NBC 10 - FOX 14 Monroe· 2 days ago82% (n=9/11) of patients on felzartamab experienced resolution of antibody-mediated rejection per Banff criteria on biopsy at 24 weeks versus 20% (n=2/10) who received placebo, and patients ...
Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio with Agreement to Acquire Human...
Morningstar· 5 days agoBiogen Inc. (Nasdaq: BIIB) and Human Immunology Biosciences (HI-Bio™), a privately-held clinical-stage biotechnology company focused on targeted therapies for patients with severe immune-mediated ...
HI-Bio Presents Positive Interim Results from Phase 2 IGNAZ Study of Felzartamab in IgA Nephropathy...
WKRN Nashville· 3 days agoPatients receiving nine-dose regimen over five months experienced deep and durable reduction in proteinuria, reaching up to ~50% mean reduction in UPCR at end of study at month 24 and over 18 ...